Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from
Caladrius Biosciences (NASDAQ:CLBS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Caladrius Biosciences will report an earnings per share (EPS) of $-0.10.
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend
Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.